Literature DB >> 20198480

Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis.

Brian C Kraemer1, Theresa Schuck, Jeanna M Wheeler, Linda C Robinson, John Q Trojanowski, Virginia M Y Lee, Gerard D Schellenberg.   

Abstract

Abnormal TDP-43 aggregation is a prominent feature in the neuropathology of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration. Mutations in TARDBP, the gene encoding TDP-43, cause some cases of ALS. The normal function of TDP-43 remains incompletely understood. To better understand TDP-43 biology, we generated mutant mice carrying a genetrap disruption of Tardbp. Mice homozygous for loss of TDP-43 are not viable. TDP-43 deficient embryos die about day 7.5 of embryonic development thereby demonstrating that TDP-43 protein is essential for normal prenatal development and survival. However, heterozygous Tardbp mutant mice exhibit signs of motor disturbance and muscle weakness. Compared with wild type control littermates, Tardbp (+/-) animals have significantly decreased forelimb grip strength and display deficits in a standard inverted grid test despite no evidence of pathologic changes in motor neurons. Thus, TDP-43 is essential for viability, and mild reduction in TDP-43 function is sufficient to cause motor deficits without degeneration of motor neurons.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20198480      PMCID: PMC2880609          DOI: 10.1007/s00401-010-0659-0

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  51 in total

1.  Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model.

Authors:  Yasumasa Yoshiyama; Makoto Higuchi; Bin Zhang; Shu-Ming Huang; Nobuhisa Iwata; Takaomi C Saido; Jun Maeda; Tetsuya Suhara; John Q Trojanowski; Virginia M-Y Lee
Journal:  Neuron       Date:  2007-02-01       Impact factor: 17.173

2.  Profound ataxia in complexin I knockout mice masks a complex phenotype that includes exploratory and habituation deficits.

Authors:  Dervila Glynn; Cheney J Drew; Kerstin Reim; Nils Brose; A Jennifer Morton
Journal:  Hum Mol Genet       Date:  2005-07-06       Impact factor: 6.150

3.  Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Manuela Neumann; Deepak M Sampathu; Linda K Kwong; Adam C Truax; Matthew C Micsenyi; Thomas T Chou; Jennifer Bruce; Theresa Schuck; Murray Grossman; Christopher M Clark; Leo F McCluskey; Bruce L Miller; Eliezer Masliah; Ian R Mackenzie; Howard Feldman; Wolfgang Feiden; Hans A Kretzschmar; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2006-10-06       Impact factor: 47.728

4.  Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice.

Authors:  Edward C Stack; James K Kubilus; Karen Smith; Kerry Cormier; Steven J Del Signore; Emmanuel Guelin; Hoon Ryu; Steven M Hersch; Robert J Ferrante
Journal:  J Comp Neurol       Date:  2005-10-03       Impact factor: 3.215

5.  TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation.

Authors:  Chun-Feng Tan; Hiroto Eguchi; Asako Tagawa; Osamu Onodera; Takuya Iwasaki; Akira Tsujino; Masatoyo Nishizawa; Akiyoshi Kakita; Hitoshi Takahashi
Journal:  Acta Neuropathol       Date:  2007-02-27       Impact factor: 17.088

6.  TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein.

Authors:  Michael J Strong; Kathryn Volkening; Robert Hammond; Wencheng Yang; Wendy Strong; Cheryl Leystra-Lantz; Christen Shoesmith
Journal:  Mol Cell Neurosci       Date:  2007-03-20       Impact factor: 4.314

7.  Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy.

Authors:  Matthew E R Butchbach; Jonathan D Edwards; Arthur H M Burghes
Journal:  Neurobiol Dis       Date:  2007-05-05       Impact factor: 5.996

8.  Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.

Authors:  Ian R A Mackenzie; Eileen H Bigio; Paul G Ince; Felix Geser; Manuela Neumann; Nigel J Cairns; Linda K Kwong; Mark S Forman; John Ravits; Heather Stewart; Andrew Eisen; Leo McClusky; Hans A Kretzschmar; Camelia M Monoranu; J Robin Highley; Janine Kirby; Teepu Siddique; Pamela J Shaw; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

9.  TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease.

Authors:  Catalina Amador-Ortiz; Wen-Lang Lin; Zeshan Ahmed; David Personett; Peter Davies; Ranjan Duara; Neill R Graff-Radford; Michael L Hutton; Dennis W Dickson
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

10.  Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases.

Authors:  Hanae Nakashima-Yasuda; Kunihiro Uryu; John Robinson; Sharon X Xie; Howard Hurtig; John E Duda; Steven E Arnold; Andrew Siderowf; Murray Grossman; James B Leverenz; Randy Woltjer; Oscar L Lopez; Ronald Hamilton; Debby W Tsuang; Douglas Galasko; Eliezer Masliah; Jeffrey Kaye; Christopher M Clark; Thomas J Montine; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2007-07-25       Impact factor: 17.088

View more
  154 in total

Review 1.  Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration.

Authors:  Edward B Lee; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2011-11-30       Impact factor: 34.870

2.  Transcription factors expressed in olfactory bulb local progenitor cells revealed by genome-wide transcriptome profiling.

Authors:  Gordon R O Campbell; Ariane Baudhuin; Karen Vranizan; John Ngai
Journal:  Mol Cell Neurosci       Date:  2010-12-29       Impact factor: 4.314

Review 3.  Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.

Authors:  Daisuke Ito; Norihiro Suzuki
Journal:  Neurology       Date:  2011-09-28       Impact factor: 9.910

4.  The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth.

Authors:  Claudia Fallini; Gary J Bassell; Wilfried Rossoll
Journal:  Hum Mol Genet       Date:  2012-05-28       Impact factor: 6.150

5.  TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD.

Authors:  Jonathan P Ling; Olga Pletnikova; Juan C Troncoso; Philip C Wong
Journal:  Science       Date:  2015-08-07       Impact factor: 47.728

6.  Temporal Expression of Mutant TDP-43 Correlates with Early Amyotrophic Lateral Sclerosis Phenotype and Motor Weakness.

Authors:  Qihua Chen; Jinxia Zhou; Cao Huang; Bo Huang; Fangfang Bi; Hongxia Zhou; Bo Xiao
Journal:  Curr Neurovasc Res       Date:  2018       Impact factor: 1.990

Review 7.  TDP43 and RNA instability in amyotrophic lateral sclerosis.

Authors:  Kaitlin Weskamp; Sami J Barmada
Journal:  Brain Res       Date:  2018-01-31       Impact factor: 3.252

Review 8.  Amyotrophic lateral sclerosis--a model of corticofugal axonal spread.

Authors:  Heiko Braak; Johannes Brettschneider; Albert C Ludolph; Virginia M Lee; John Q Trojanowski; Kelly Del Tredici
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

Review 9.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

10.  Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth.

Authors:  Bettina Schmid; Alexander Hruscha; Sebastian Hogl; Julia Banzhaf-Strathmann; Katrin Strecker; Julie van der Zee; Mathias Teucke; Stefan Eimer; Jan Hegermann; Maike Kittelmann; Elisabeth Kremmer; Marc Cruts; Barbara Solchenberger; Laura Hasenkamp; Frauke van Bebber; Christine Van Broeckhoven; Dieter Edbauer; Stefan F Lichtenthaler; Christian Haass
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.